Skip to content

08037.HK

China Biotech Services Holdings Limited

HKSE · Healthcare · Medical - Diagnostics & Research · HK

HKD 0.60
+0.00%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
EBIT
EPS
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
-65.9%
EBITDA
+41.0%
EBIT
+46.9%
Net income
+65.3%
EPS
+64.8%
Free cash flow
+3.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026